Street check leads to 4.25 oz. fentanyl bust, weapons found: Jamestown police
City of Jamestown police have charged 19-year-old Marquan Cunningham-Carper with felony counts of drug and weapon charges after arresting him during a street check around 1:40 p.m. on May 20.
Meadville woman arrested after 100 mph chase involving three departments
Cunningham-Carper was already wanted by Jamestown police for criminal sale of a controlled substance when he was spotted at a local store in the 600 block of Newland Ave. and allegedly tried to throw away a baggie that had about 4.25 oz. of fentanyl pills before he could be detained.
A search warrant was performed at his home, where police said they found Lorazepam pills, digital scales, cutting agents, cell phones, a .38 special revolver, a high-capacity pistol magazine and $550 cash.
Three arrested, face dozens of charges for alleged involvement in PA fentanyl operation
Cunningham-Carper is facing second, third, and seventh-degree criminal possession of a controlled substance, two counts of criminally using drug paraphernalia, along with second and third-degree criminal possession of a weapon to go with the criminal sale of a controlled substance charge he was wanted for.
He was arraigned on the criminal sale of a controlled substance charge on May 27 and pleaded not guilty. No court information was available for the new charges.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Crews battle huge fire in North Las Vegas; 1 person injured
LAS VEGAS (KLAS) — A massive fire in North Las Vegas on Tuesday morning raged at a site where apartments are under construction. The black smoke could be seen from around the valley. More than one building was involved in the fire, according to Kathleen Richards, North Las Vegas communications manager. A construction worker was injured in the fire. He was transported to University Medical Center with burn injuries, and a second person is being evaluated at the scene, Richards said. The fire was reported around 7 a.m. at 6500 N. Fifth Street, near Centennial Parkway in what appears to be an apartment complex under construction. Northbound 5th Avenue is currently closed to traffic at Centennial Parkway. Crews will remain on the site to check for hot spots. This is a developing story. Please check back for details. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down
Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 17 cents in second-quarter 2025 compared with the year-ago period's EPS of 6 cents. However, the metric missed the Zacks Consensus Estimate by a penny. HIMS' Revenues in Detail Hims & Hers registered revenues of $544.8 million in the second quarter, up 72.6% year over year. The figure missed the Zacks Consensus Estimate by 1.5%. Solid revenues from the Online channel drove the top line despite being partially offset by Wholesale revenues. Shares of this company lost nearly 12.9% in today's pre-market trading. Hims & Hers' Segment Details Hims & Hers' operations consist of two channels — Online Revenues and Wholesale Revenues. In the quarter under review, Online Revenues of $536.9 million reflected a surge of 74.9% year over year on a reported basis. During the reported quarter, subscribers were 2.4 million (up 30.8% year over year). This was primarily driven by increased traffic to Hims & Hers' platform (through websites and mobile applications), resulting from its marketing activities and improved onsite and customer onboarding experiences and consumer adoption of the company's personalized offerings across its business, including GLP-1 weight loss offerings. Monthly online revenue per average subscriber increased 29.8% year over year to $74 in the second quarter, primarily resulting from subscriber uptake of personalized offerings across Hims & Hers' business, including its GLP-1 weight loss offering, along with changes in product mix. Wholesale Revenues totaled $7.9 million, down 9.7% year over year. Hims & Hers Health, Inc. Price, Consensus and EPS Surprise Hims & Hers Health, Inc. price-consensus-eps-surprise-chart | Hims & Hers Health, Inc. Quote HIMS' Margin Analysis In the second quarter, Hims & Hers' gross profit increased 62.2% year over year to $416.2 million. However, the gross margin contracted 491 basis points (bps) to 76.4%. Marketing expenses jumped 50.3% year over year to $217.9 million, while technology and development expenses increased 102.9% year over year to $37.8 million. General and administrative expenses rose 65.9% year over year to $67.3 million, while operations and support expenses increased 60.4% year over year to $66.5 million. Operating expenses of $389.5 million increased 58.6% year over year. Operating profit totaled $26.7 million, reflecting a 142.3% surge from the year-ago quarter. The operating margin in the second quarter expanded 141 bps to 4.9%. Hims & Hers' Financial Position Hims & Hers exited second-quarter 2025 with cash and cash equivalents and short-term investments of $1.14 billion compared with $322.7 million at the first-quarter end. Cumulative net cash provided by operating activities at the end of second-quarter 2025 was $89.9 million compared with $79.4 million a year ago. HIMS' Outlook Hims & Hers has provided its revenue outlook for the third quarter and reiterated the same for 2025. The company projects revenues for the third quarter of 2025 in the range of $570 million to $590 million, reflecting an uptick of 42-47% year over year. The Zacks Consensus Estimate is pegged at $583.3 million. For the full year, the company continues to project revenues in the range of $2.3 billion to $2.4 billion (representing growth of 56-63% from 2024 levels). The Zacks Consensus Estimate is pegged at $2.35 billion. Our Take on Hims & Hers Hims & Hers' robust improvement in the top and bottom lines and strength in its Online revenue channel in second-quarter 2025 were promising. The increase in subscribers and monthly online revenue per average subscriber during the quarter was encouraging. The expansion of the operating margin during the quarter bodes well. In July, HIMS closed its acquisition of ZAVA, expanding its presence in the U.K. and establishing a foundation in other strategic markets such as Germany, Ireland and France. Per management, the acquisition will likely accelerate the company's ability to expand into markets beyond Europe. In 2026, Hims & Hers expects to enter Canada with an initial focus on a holistic weight loss program, timed to align with the anticipated first-ever availability of generic semaglutide globally. These raise our optimism about the stock. However, Hims & Hers' lower-than-expected results in the second quarter of 2025 and lower Wholesale revenues were disappointing. The gross margin contracted due to rising product costs, which do not bode well for the stock. HIMS' Zacks Rank and Other Key Picks Hims & Hers currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 hours ago
- Business Wire
SCH Capital Holdings, Inc. Adds Health Care Compensation Management Technology Capability to Portfolio
CHICAGO--(BUSINESS WIRE)--SCH Capital Holdings, Inc., the nation's leading human capital information management holding company for health care and not-for-profit/tax-exempt organizations, has acquired Boston-based Statera. "When we combine Statera's focus on academic medical centers alongside Clinician Nexus's integrated delivery systems expertise, we are able to serve the entire health care marketplace with specialized compensation management expertise in both segments." Formed in 2020, Statera is a group of human-focused compensation experts and health care technologists who provide timely and actionable compensation and care insights to hospitals, medical groups, and clinicians. Statera's platform offers a comprehensive suite of tools that optimize clinical team performance and automate compensation administration. Statera will continue to enable health systems to automate physician compensation through its technology platform as part of Clinician Nexus, a SCH Capital Holdings, Inc. technology company. Together, these combined capabilities will provide health care organizations with a broad mix of technology tools that empower health systems and medical groups to align compensation, productivity, and incentives for their physicians and APPs. 'When we combine Statera's focus on academic medical centers alongside Clinician Nexus's integrated delivery systems expertise, we are able to serve the entire health care marketplace with specialized compensation management expertise in both segments,' said Ted Chien, President and CEO of SCH Capital Holdings, Inc. 'We are excited to join the SCH Capital Holdings, Inc., family and integrate our expertise into the Clinician Nexus brand,' said Amy Jackson, CEO of Statera. 'The company's gold standard reputation and Clinician Nexus's established platform will enable us to reach new markets. Together, we'll be able to deliver the next generation of compensation management technology to a broader audience and make a greater impact across the health care ecosystem.' About SCH Capital Holdings, Inc. SCH Capital Holdings, Inc., is the parent company of independent operating brands SullivanCotter, Clinician Nexus, Lotis Blue Consulting and C3 Nonprofit Consulting Group. This collection of complementary brands helps organizations solve complex workforce issues by enabling people, processes and technology aimed at large-scale business transformation. For more information, email info@ or call 888.739.7039.
